Agomelatine, an antidepressant used to treat major depressive disorder, was developed in the 1990s and approved for medical use in the late 2000s in several countries; its history is marked by a novel mechanism of action as a melatonergic agonist and serotonin receptor antagonist, which helps regulate circadian rhythms and improve sleep patterns in patients with depression, as well as concerns over potential liver toxicity that led to recommendations for routine liver function monitoring before and during treatment, and it was first approved in Europe in 2009 as a monotherapy, with its development highlighting a distinct pharmacological profile compared to traditional antidepressants alongside post-marketing surveillance programs to ensure early detection and management of adverse effects.
BRAND NAMES
Agomelatine is marketed under several brand names, the most widely recognized being Valdoxan, along with others such as Melitor, Thymanax, and Agotin, depending on the country and manufacturer.
MECHANISM OF ACTION
Agomelatine works through a unique dual mechanism: it acts as an agonist at melatonin receptors (MT1 and MT2), helping to resynchronize disrupted circadian rhythms and improve sleep–wake cycles, and as an antagonist at serotonin 5-HT2C receptors, which leads to increased release of dopamine and norepinephrine in the frontal cortex; this combined effect contributes to its antidepressant properties without significantly affecting serotonin reuptake, distinguishing it from many traditional antidepressants.
PHARMACOKINETICS
Absorption
Agomelatine is rapidly absorbed after oral administration, with peak plasma concentrations typically reached within 1–2 hours; however, its absolute bioavailability is low (less than 5%) due to extensive first-pass metabolism in the liver, and food has minimal effect on its absorption, allowing it to be taken with or without meals.
Distribution
Agomelatine is widely distributed throughout the body and exhibits a high degree of plasma protein binding (approximately 95%), mainly to albumin and alpha-1-acid glycoprotein; it has a moderate volume of distribution, allowing effective penetration into central nervous system tissues, which is essential for its therapeutic action in depression.
Metabolism
Agomelatine is extensively metabolized in the liver, primarily by cytochrome P450 enzymes, especially CYP1A2, with minor contributions from CYP2C9 and CYP2C19; it undergoes hydroxylation and demethylation to form inactive metabolites, which are subsequently conjugated and prepared for elimination, contributing to its low systemic bioavailability.
Elimination
Agomelatine is eliminated primarily via the kidneys in the form of its metabolites, with about 80% excreted in urine and a smaller proportion in feces; it has a relatively short elimination half-life of approximately 1–2 hours, reflecting its rapid clearance from the body after hepatic metabolism.
Pharmacodynamics
Agomelatine exerts its antidepressant effects through a unique interaction with central nervous system receptors, acting as an agonist at melatonin MT1 and MT2 receptors to regulate circadian rhythms and improve sleep quality, while simultaneously antagonizing serotonin 5-HT2C receptors, which enhances the release of dopamine and norepinephrine in the frontal cortex; this dual action helps alleviate depressive symptoms, improve mood, and restore normal sleep–wake cycles without significantly affecting serotonin reuptake or causing typical side effects associated with conventional antidepressants.
Administration
Agomelatine is administered orally, typically once daily at bedtime, with or without food. The usual recommended starting dose is 25 mg per day, which may be increased to 50 mg per day if the therapeutic response is insufficient after a few weeks. Due to its potential for liver toxicity, liver function tests should be performed before starting treatment, periodically during therapy, and as clinically indicated.
Dosage and strength
Agomelatine is usually prescribed in oral tablet form, with standard strengths of 25 mg and 50 mg per tablet. The typical starting dose is 25 mg once daily at bedtime, which can be increased to 50 mg once daily if the clinical response is inadequate after 2 weeks. The maximum recommended duration depends on individual response, and treatment should be regularly evaluated, with liver function monitoring throughout therapy.
Drug Interactions
Agomelatine is mainly metabolized by CYP1A2, so co-administration with strong CYP1A2 inhibitors like fluvoxamine or ciprofloxacin can increase plasma levels and the risk of liver toxicity, while CYP1A2 inducers such as rifampicin or tobacco smoke may reduce its effectiveness. Caution is also needed with other hepatotoxic drugs, and interactions with medications metabolized by CYP2C9 or CYP2C19 are generally minimal.
Food Interactions
Agomelatine can be taken with or without food, as food has minimal effect on its absorption or overall bioavailability. However, patients are advised to avoid excessive alcohol consumption during treatment, since alcohol can increase the risk of liver toxicity, which is already a concern with agomelatine therapy.
Contraindications
Agomelatine is contraindicated in patients with severe liver impairment, active liver disease, or hypersensitivity to the drug, and should be used cautiously with strong CYP1A2 inhibitors, heavy alcohol use, or during pregnancy and breastfeeding.
Side Effects
Agomelatine is generally well tolerated, but common side effects include headache, dizziness, nausea, diarrhea, and fatigue. Less frequently, it can cause insomnia, anxiety, and increased liver enzymes, which is why regular liver function monitoring is recommended during treatment. Rarely, severe liver injury may occur.
Toxicity
Agomelatine toxicity is primarily hepatotoxic, with elevated liver enzymes reported in some patients, particularly at higher doses or in those with preexisting liver conditions. Symptoms of overdose may include somnolence, confusion, or gastrointestinal disturbances, but serious toxicity is rare. Liver function monitoring is essential to detect early signs of hepatotoxicity.
